Zoetis
Ticker: ZTS US
Sector: Animal Health
Rating: Buy
Published Research
Zoetis: Q1 Reassured on New Competitors, Librela & Tariffs (May 2025)
Zoetis: Strong 2024 Finish, Confusing 2025 Outlook? (February 2025)
Zoetis: Down 10%+ in Past Year Despite Strong YTD Results (December 2024)
Zoetis: EPS Growth to Reaccelerate, But Shares Down 14% YTD (March 2024)
Legacy Seeking Alpha Articles
Zoetis: Back On Track In Q4, Regaining Premium Valuation (February 2023)
Zoetis: EPS Down In Q3, Due To FX & Supply Chain Disruption (November 2022)
Zoetis: Strong Q2 Underlying Growth But Hit By Strong USD (August 2022)
Zoetis: Animal Health Leader Now Cheapest Since April 2021 (May 2022)
Zoetis: Upgrade To Buy After 22% Fall From Peak & Strong Q4 (February 2022)
Zoetis: Record Share Price & 52x P/E May Not Last Into 2022 (December 2021)
Zoetis: Growth To Normalize After Q2; Overvalued At 48x P/E (August 2021)
Zoetis: Downgrade To Neutral After Record High & 44x P/E (July 2021)
Zoetis: 3.7% Dip Despite Strong Q1 And Raised 2021 Outlook (May 2021)
Multi-Year Compounder On Sale Again After 14% Correction (March 2021)
Sales Growth Rebounded To 15% In Q3 But P/E Is Now 43x (November 2020)
Downgrade To Neutral On Valuation After 37% Gain (September 2020)
Continuing Resilience And Compounding At 10%+ Annually (March 2020)
Near-Term Headwinds, But Long-Term 10% Annual Growth (November 2019)